CHICAGO--(BUSINESS WIRE)--Syntax Bio, a preclinical-stage biotechnology company, has launched with backing from Astellas Venture Management LLC and Illumina Ventures. Other investors include DCVCBio, ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company's CRISPR-based ...
NEW YORK--(BUSINESS WIRE)--Syntax Health, Inc., an enterprise SaaS-based solution for health plans and providers that accelerates alignment in value-based care (VBC), today announced the launch of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback